Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer

This is a randomized, controlled, multicenter clinical study to evaluate AK104 in FIGO 2018 stage III-IV ovarian cancer subjects who were assessed to be at high perioperative risk and/or unable to achieve R0 resection prior to initial treatment. The efficacy and safety of neoadjuvant therapy with intravenous infusion combined with chemotherapy compared with chemotherapy alone.

Trial Details

NCT ID
NCT06542549
Phase
PHASE3
Sponsor
Anhui Provincial Hospital
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • AK104
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • Agree to sign the informed consent form.
  • 18 years ≤ age \<75 years, female.
  • Patients with histopathologically confirmed epithelial ovarian cancer (high-grade serous adenocarcinoma, endometrioid adenocarcinoma of the ovary, …
  • Evidence of compliance with neoadjuvant chemotherapy for ovarian cancer: (a) Preoperative evaluation by gynecologic oncologists (multidisciplinary …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →